The HCC Treatment Crisis Hepatocellular carcinoma (HCC), the most common primary liver cancer, represents approximately 90% of liver malignancies. It is the third most common cause of cancer-related mortality globally. Despite its prevalence and lethality, sorafenib remains the only FDA-approved first-line therapy for advanced HCC, offering a modest 2.5-month survival benefit with a less than 5% response rate. More than ten other drugs have failed in phase III clinical trials.
The Genomic Revolution Recent large-scale genomic sequencing studies have identified 161 putative genetic alterations in HCC, enabling systematic analysis of the molecular landscape. These include mutations in signaling pathways (WNT, TP53, PI3K/AKT/mTOR), chromatin remodeling genes (ARID1A, ARID2), and epigenetic regulators (TERT). Understanding these alterations is essential for developing targeted therapies and biomarker-matched treatment strategies.
Immunotherapy Emergence In parallel with genomic insights, immunotherapy with checkpoint inhibitors has emerged as a major new treatment approach. The finding that 82% of HCC tumors express PD-L1 by immunohistochemistry, combined with approximately 19% response rates to anti-PD-1 treatment (including about 5% complete remissions), establishes immunotherapy as a meaningful treatment option requiring further optimization.
Etiology-Linked Mutation Profiles HCC genomic portfolios cluster into risk factor-linked groups: CTNNB1 mutations (activating WNT/beta-catenin signaling) are associated with alcoholic cirrhosis; TP53 mutations are associated with hepatitis B virus (HBV)-induced cirrhosis; while HCV, metabolic syndrome, and hemochromatosis-related HCC show less distinct mutation patterns. This etiology-genomics relationship helps explain why HCC behaves differently in different geographic and demographic settings.
Stage-Dependent Alterations Genomic analyses have revealed temporal ordering of mutations during HCC progression. TERT promoter mutations appear more frequently in early-stage tumors, suggesting they are early driver events. In contrast, TP53 mutations, CDKN2A alterations, and amplification of the chromosome 11 amplicon (containing FGF3, FGF4, FGF19, and CCND1) are more common in advanced stages, suggesting they contribute to malignant progression rather than initiation.
Most Frequent Alterations The most commonly mutated genes in HCC are TERT promoter (up to 44%), TP53 (13-48%), CTNNB1 (11-41%), AXIN1 (5-19%), ARID1A (4-17%), CDKN2A (4%), and CCND1. PTEN protein loss is frequent even in tumors without PTEN mutation, likely due to post-translational regulation. These alterations affect key biological processes including telomere maintenance, p53 tumor suppression, WNT signaling, and chromatin remodeling.
CTNNB1 and AXIN1 as Dual Targets The WNT/beta-catenin pathway is the most frequently altered signaling pathway in HCC. Activating mutations in CTNNB1 (11-41%) and inactivating mutations in AXIN1 (5-19%) both produce the same functional outcome: constitutive beta-catenin activation driving proliferation. Because they act in the same pathway, these mutations are typically mutually exclusive.
Therapeutic Approaches Multiple WNT pathway inhibitors are being tested: PRI-724 (a beta-catenin/CBP inhibitor) and BBI608 (a STAT3/stem cell pathway inhibitor) are in clinical trials. Beyond direct WNT inhibitors, evidence suggests that NSAIDs (celecoxib, sulindac), gamma secretase inhibitors, and sorafenib may all modulate WNT/beta-catenin signaling. Beta-catenin suppression in mouse HCC models has produced complete responses, providing strong preclinical rationale.
AXIN Stabilization Strategy An alternative approach targets AXIN1 stabilization. The enzymes tankyrase 1 and tankyrase 2 promote AXIN degradation; inhibiting them with the small molecule XAV939 stabilizes AXIN and suppresses beta-catenin. This represents a druggable mechanism distinct from direct CTNNB1 targeting, potentially active in both CTNNB1-mutant and AXIN1-mutant HCC subsets.
TP53 Alterations and Consequences TP53 mutations (13-48% of HCCs, most common in HBV-associated tumors) correlate with worse clinical stage and prognosis. TP53 loss deactivates the cell's key tumor suppressor and apoptosis inducer. Anti-angiogenic agents (like bevacizumab) have shown improved progression-free survival specifically in TP53-mutant HCC patients. Wee1 kinase inhibitors, which exploit the G2 checkpoint loss in TP53-mutant cells, are also in clinical evaluation for HCC.
PTEN Loss and PI3K Pathway PTEN protein loss is frequent in HCC (often without PTEN mutation, suggesting epigenetic or post-translational mechanisms). PTEN loss activates the PI3K/AKT/mTOR pathway, driving tumor cell survival and proliferation. ARID1A-deficient tumors also show PI3K/AKT pathway activation, and preclinical studies demonstrate that ARID1A-deficient tumors are sensitive to PI3K/AKT/mTOR pathway inhibitors, suggesting a synthetic lethality approach.
MDM4 as Emerging Target MDM4 amplification in HCC without TP53 mutation represents a mechanism of p53 pathway inactivation without direct p53 mutation - and an opportunity for therapeutic restoration of p53 function using MDM4 inhibitors. This approach could benefit the subset of HCC patients whose tumors have functional but suppressed p53 protein.
PD-L1 Expression and Checkpoint Therapy Immunohistochemical analysis shows PD-L1 expression in 82% of HCC tumors. Clinical trials of anti-PD-1 antibodies (nivolumab, pembrolizumab) have demonstrated approximately 19% objective response rates in HCC, including about 5% complete remissions - responses that can be durable. These results are remarkable for a cancer where essentially no systemic therapies had shown consistent single-agent activity.
Biomarker Challenges Despite these encouraging results, the majority of HCC patients do not respond to checkpoint blockade. PD-L1 expression alone is an imperfect predictor of response, and biomarker-matched trials are limited. Understanding which patients are most likely to respond based on tumor mutational burden, tumor-infiltrating lymphocyte density, specific mutation patterns (CTNNB1-mutant HCC may be immune-cold), or viral etiology is an active area of research.
Combination Strategy Rationale The relatively modest single-agent response rates suggest that combination approaches are needed. Combining checkpoint inhibitors with anti-angiogenic agents (to normalize the immunosuppressive vascular environment), targeted therapies (sorafenib, lenvatinib), or other immune modulators may produce synergistic anti-tumor effects. The diverse molecular landscape of HCC - with different targetable alterations in different patients - suggests that personalized combination regimens will ultimately be required.
Anti-Angiogenic Therapy HCC is a highly vascular tumor, and VEGFA amplification occurs in about 8% of cases. Sorafenib's clinical activity (the only approved first-line drug) acts partly through VEGFR inhibition. Newer anti-angiogenic approaches include lenvatinib (approved second-line), regorafenib, and cabozantinib. MET amplification (7% of HCC) and CCND1 amplification represent additional kinase targets for specific HCC subpopulations.
Epigenetic Targets IDH1 mutations occur in a small subset of HCC (particularly intrahepatic cholangiocarcinoma-like tumors) and are targetable by ivosidenib, an approved IDH1 inhibitor. MCL1 amplification (observed in HCC with 1q21 gain) represents an anti-apoptotic vulnerability potentially targetable by BCL-2/MCL1 family inhibitors. TERT overexpression suggests telomerase inhibition as a potential target for the 44% of HCC with TERT promoter mutations.
Fibrolamellar Carcinoma A subset of liver cancer requires separate consideration. Fibrolamellar carcinoma - rare, occurring in young patients without underlying liver disease - harbors a specific DNAJB1-PRKACA fusion gene in 79-100% of cases, creating an oncogenic kinase fusion. This fusion represents a highly specific therapeutic target unique to fibrolamellar carcinoma, completely distinct from conventional HCC biology.
Need for Biomarker-Matched Trials This review highlights that many genomic alterations in HCC are potentially druggable with existing agents, but clinical translation has been hampered by treating HCC as a molecularly homogeneous disease. Basket trials enrolling HCC patients based on specific molecular alterations (CTNNB1, TP53, FGFR2, IDH1) rather than by histology alone represent the most promising path forward.
Combining Genomics and Immunotherapy Future treatment strategies will likely require integration of genomic profiling and immune biomarkers to rationally combine targeted therapy with immunotherapy. The etiology-linked genomic subgroups (HBV-TP53, alcohol-CTNNB1, HCV-others) may respond differently to immunotherapy, and viral-specific immune factors may influence checkpoint inhibitor efficacy independently of tumor genomics.
Liquid Biopsy and Real-Time Monitoring Cell-free DNA (cfDNA) analysis in plasma offers the potential for non-invasive HCC genomic profiling, treatment response monitoring, and early relapse detection. Tracking the clonal evolution of targetable mutations in HCC over the course of therapy could inform rational treatment sequencing and identify mechanisms of acquired resistance before clinical progression.